With a deeper exploration, we found that the expression level of TRHDE-AS1 was correlated to clinical features such as grade, histology, IDH mutation, etc. In previous research, the prognosis of glioblastoma is the worst, with less than 14 months of median survival while the prognosis of oligodendroglioma is the one of the best, which is the same as our results. This evidence concerns the gene TRHDE and oligodendroglioma.